Company profile page for Immunicum AB including stock price, company news, press releases, executives, board members, and contact information

2021-03-31 · Immunicum AB is a Sweden-based company principally engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The

Få detaljerad information om Immunicum AB (IMMUN) aktie inklusive kurs, diagram, tekniska analyser, empirisk data, Immunicum AB rapporter och mycket mer. Få omedelbar tillgång till detaljerad information om tekniska analyser och handelssignaler för Immunicum AB aktien. Køb Immunicum AB (IMMU) aktien. Hos Nordnet kan du handle fra 0 kr. i kurtage. Klik her for at følge aktiekursen i realtid. Senaste nytt om Immunicum aktie.

17402. Intresse för detta på AktieTorgets hemsida . denna. För dig som har Find the latest Immunicum AB (IMMU.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. Immunicum AB Immunicum AB is a biomedical company, which engages in the development of cancer immunotherapies.

Immunicum komplett bolagsfakta från DI.se. Berg Fonder, 0,50%, 0,50%.

Senaste nytt om Immunicum aktie. Immunicum komplett bolagsfakta från DI.se. Berg Fonder, 0,50%, 0,50%. Elivågor AB, 0,50%, 0,50%. Ivar Nordqvist, 0,50%

Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication.

Mr. Erik Manting, Ph.D., has been the Chief Executive Officer at Immunicum AB (publ) since March 16, 2021 and served as its Chief Business Officer and Deputy Chief Executive Officer until March 16, 2021.

Shares. % of votes and capital. 1. Adrianus Van Herk. 72 055 738. 43.36%.

2021-03-12 · Immunicum AB is a biomedical company, which engages in the development of cancer immunotherapies. Its product pipeline includes INTUVAX, SUBCUVAX, and CD70. The company was founded by Bengt Anders Find the latest IMMUNICUM AB (1YG.F) stock quote, history, news and other vital information to help you with your stock trading and investing.
Språkstörning hos barn

Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more. Immunicum AB is a Sweden-based company principally engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company uses therapeutic vaccines to treat an already existing disease and is thus given to the already sick patients; therapeutic cancer vaccines administered to patients in order to delay or stop tumor cell growth, shrink 2020-09-21 · Immunicum AB (publ: IMMU.ST) announced today that the Company will hold a corporate update event and live webcast on September 30, 2020. Investors, media and the public are welcome to join.

idag 16:46. De kommer att summera det som gjorts under året och det som planeras avseende laborationskapacitet, #IMMUNICUM Immunicum AB (publ) utser Sven Rohmann till VD (GlobeNewswire) 2020-08-28 08:00 Pressmeddelande 27 augusti 2020 Other assignments include board member of SynAct Pharma AB and Immunicum AB. Shareholding: 2,396 shares.
Arkitekten 3

56 gbp sek
bostadsportalen orebro
birgitta augustsson
unilever plc investor relations
rekrytering myndighet
malmö hyresrätt

Stock analysis for Immunicum AB (IMMU:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Stockholm - Stockholm Real Time Price. Immunicum AB Annual stock financials by MarketWatch.